Evidence That GRIN2A Mutations in Melanoma Correlate with Decreased Survival
Open Access
- 1 January 2014
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
Abstract
Previous whole-exome sequencing has demonstrated that melanoma tumours harbour mutations in the GRIN2A gene. GRIN2A encodes the regulatory GluN2A subunit of the glutamate-gated N-methyl-D-aspartate receptor (NMDAR), involvement of which in melanoma remains undefined. Here, we sequenced coding exons of GRIN2A in 19 low-passage melanoma cell lines derived from patients with metastatic melanoma. Potential mutation impact was evaluated in silico, including within the GluN2A crystal structure, and clinical correlations were sought. We found that of 19 metastatic melanoma tumours, four (21%) carried five missense mutations in the evolutionarily conserved domains of GRIN2A; two were previously reported. Melanoma cells that carried these mutations were treatment-naïve. SIFT analysis predicted that S349F, G762E and P1132L would disrupt protein function. When modelled into the crystal structure of GluN2A, G762E was seen to potentially alter GluN1-GluN2A interactions and ligand binding, implying disruption to NMDAR functionality. Patients whose tumours carried nonsynonymous GRIN2A mutations had faster disease progression and shorter overall survival (P < 0.05). This was in contrast to the BRAF V600E mutation, found in 58% of tumours but showing no correlation with clinical outcome (P = 0.963). Although numbers of patients in this study are small, and firm conclusions about the association between GRIN2A mutations and poor clinical outcome cannot be drawn, our results highlight the high prevalence of GRIN2A mutations in metastatic melanoma and suggest for the first time that mutated NMDARs impact melanoma progression.Keywords
This publication has 27 references indexed in Scilit:
- Hijacking the Neuronal NMDAR Signaling Circuit to Promote Tumor Growth and InvasionCell, 2013
- Which drug, and when, for patients with BRAF-mutant melanoma?The Lancet Oncology, 2013
- Exome sequencing identifies recurrent somatic RAC1 mutations in melanomaNature Genetics, 2012
- A Landscape of Driver Mutations in MelanomaCell, 2012
- Melanoma genome sequencing reveals frequent PREX2 mutationsNature, 2012
- Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanomaNature Genetics, 2011
- Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencingNature Genetics, 2011
- Exome sequencing identifies GRIN2A as frequently mutated in melanomaNature Genetics, 2011
- Glutamate Receptor Ion Channels: Structure, Regulation, and FunctionPharmacological Reviews, 2010
- A nomenclature for ligand-gated ion channelsNeuropharmacology, 2009